5Bennett J M, Orazi A. Diagnostic criteria to distinguish hy- pocellular acute myeloid leukemia from myelodysplastic syn-dromes and aplastic anemia: recommendations for a stand- ardized approach[ J]. haematologica, 2009,94(2) :264-268.
6Vardiman J W, Harris N L, Brunning R D. The World Health Organization(WHO) classification of the myeloid ne- oplasms [ J ]. blood, 2002,100 (7) :2292-2302.
7von Bubnoff N, Gorantla S P, Engh R A, et al. The low fre- quency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro [ J ]. Oncogene, 2011,30 ( 8 ) :933-943.
8Sill H, Olipitz W, Zebisch A, et al. Therapy-related mye- loid neoplasms : pathobiology and clinical characteristics [ J ]. Br J Pharmacol, 2011,162(4) :792-805.
9Ricci F, Tedeschi A, Montillo M, et al. Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstromg Macroglobulinemia[ J]. Mediterr J Hematol In- fect Dis, 2011,3(1) :31.
